Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CDC25B | P30305 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | PTPRC | P08575 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670373 | 0.70 | EHMT2 (0.40) | MEN1KMT2ACDC25BPOLBMAPT | |
| SCHEMBL2095985 | 0.64 | KMT2A (0.50) | MEN1KMT2ACDC25BPOLBMAPT | |
| Anthraquinone SCHEMBL14943 | 0.58 | MEN1 (1.00) | MEN1KMT2ACDC25BPOLBMAPT | |
| Anthraquinone SCHEMBL29358690 | 0.58 | MEN1 (1.00) | MEN1KMT2ACDC25BPOLBMAPT | |
| Anthraquinone SCHEMBL1901249 | 0.58 | MEN1 (1.00) | MEN1KMT2ACDC25BPOLBMAPT | |
| SCHEMBL2627989 | 0.58 | MEN1 (0.73) | MEN1KMT2ACDC25BPOLBMAPT | |
| SCHEMBL454827 | 0.58 | POLB (0.67) | MEN1KMT2ACDC25BPOLBMAPT | |
| Bromide SCHEMBL31530716 | 0.56 | MEN1 (0.70) | MEN1KMT2ACDC25BPOLBMAPT | |
| SCHEMBL31450384 | 0.56 | MEN1 (0.70) | MEN1KMT2ACDC25BPOLBMAPT | |
| SCHEMBL2022462 | 0.56 | POLB (0.64) | MEN1KMT2ACDC25BPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113793-A1 | Process for the Preparation of Highly Pure Donepezil | IND-SWIFT LABORATORIES LIMITED (IN) | 2010-05-06 | — | — | US | claimed |
| WO-2007108011-A2 | PROCESS FOR THE PREPARATION OF HIGHLY PURE DONEPEZIL | IND-SWIFT LABORATORIES LIMITED (IN) | 2007-09-27 | — | — | WO | claimed |
| US-5100901-A | Treatment of Alzheimer*s disease | EISAI CO., LTD. (JP) | 1992-03-31 | — | — | US | claimed |
| US-20100113793-A1 | Process for the Preparation of Highly Pure Donepezil | IND-SWIFT LABORATORIES LIMITED (IN) | 2010-05-06 | — | — | US | disclosed |
| US-20100113793-A1 | Process for the Preparation of Highly Pure Donepezil | IND-SWIFT LABORATORIES LIMITED (IN) | 2010-05-06 | — | — | US | disclosed |
| WO-2007108011-A3 | PROCESS FOR THE PREPARATION OF HIGHLY PURE DONEPEZIL | IND SWIFT LAB LTD (IN) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007108011-A2 | PROCESS FOR THE PREPARATION OF HIGHLY PURE DONEPEZIL | IND-SWIFT LABORATORIES LIMITED (IN) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007108011-A2 | PROCESS FOR THE PREPARATION OF HIGHLY PURE DONEPEZIL | IND-SWIFT LABORATORIES LIMITED (IN) | 2007-09-27 | — | — | WO | disclosed |
| EP-0971713-A1 | USE OF CHOLINESTERASE INHIBITORS TO TREAT DISORDERS OF ATTENTION | Eisai Co., Ltd. (JP) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998039000-A1 | USE OF CHOLINESTERASE INHIBITORS TO TREAT DISORDERS OF ATTENTION | EISAI CO., LTD. (JP) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113793-A1 | Process for the Preparation of Highly Pure Donepezil | PSEN1, ACHE, PSEN2 | MEN1 961/4885KMT2A 384/4885CDC25B 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.